share_log

公告精选︱哔哩哔哩三季度净亏损收窄约两成;新华保险拟与中国人寿以500亿元设私募基金

Selected Announcements|Bilibili's net loss for the third quarter narrowed by about 20%; Xinhua Insurance plans to set up a private equity fund of 50 billion yuan with China Life

Futu News ·  11/30/2023 08:22

Big announcement

1. Bilibili - SW: Q3 net loss was 1.5 billion yuan, a year-on-year narrowing of 22%

$BILIBILI-W (09626.HK)$According to the Hong Kong Stock Exchange, the total net turnover for Q3 in 2023 was 5.8 billion yuan, the same as the previous year; the net loss was 1.5 billion yuan, a decrease of 22% from the previous year; the adjusted net loss was 864 million yuan, a decrease of 51% from the previous year; and the number of daily active users was 103 million yuan, an increase of 14% over the previous year.

2. Zhihu-W: Revenue for the third quarter exceeded 1 billion yuan, up 12.1% year on year

$ZHIHU-W (02390.HK)$It was announced that total revenue for the third quarter of 2023 was approximately RMB 1,022 million (US$140 million), up 12.1% from the same period in 2022; net loss was approximately RMB 278 million, down 6.5% year on year; and adjusted net loss was approximately RMB 225 million, down 10.1% year on year.

3. Xinhua Insurance: It plans to jointly invest with China Life Insurance to establish a private equity fund. Both parties plan to invest 25 billion yuan each

$NCI (01336.HK)$It was announced that after review and approval by the board of directors on November 29, 2023, (i) the company intends to cooperate with$CHINA LIFE (02628.HK)$To jointly fund the establishment of a private equity fund, both parties plan to invest RMB 25 billion each; and (ii) Xinhua Asset, a subsidiary of the company, and China Life Insurance Asset, a subsidiary of China Life Insurance, will jointly initiate the establishment of a fund manager company. Both parties plan to invest RMB 5 million each. As of the date of the announcement, the relevant parties had not entered into an agreement on the establishment of a joint venture fund and a joint venture fund manager company.

4. Yankuang Energy: Controlling shareholders plan to spend RMB 300 million to increase their holdings of the company's A shares and H shares

$YANKUANG ENERGY (01171.HK)$It was announced that the controlling shareholder Shandong Energy has been notified by the controlling shareholder Shandong Energy that it intends to increase its holdings of the Company's A shares and H shares with its own capital and self-raised funds within 12 months from the date of this announcement. The cumulative increase in holdings is not less than RMB 300 million and not more than RMB 600 million. Among them, the cumulative increase in A-share holdings is not less than RMB 100 million, not more than RMB 200 million; the cumulative increase in H-share holdings is not less than RMB 200 million, not more than RMB 400 million.

Earnings Report

$BILIBILI-W (09626.HK)$Q3 net loss was 1.5 billion yuan, a year-on-year narrowing of 22%

$ZHIHU-W (02390.HK)$Revenue in the third quarter exceeded 1 billion yuan and continued to grow, and paid membership revenue increased 39.2% year over year

$LUK FOOK HOLD (00590.HK)$: Interim net profit increased by 43.3% to HK$900 million Interim interest of HK$0.72

$MAPLELEAF EDU (01317.HK)$Annual adjusted net profit of 136 million yuan increased 197.8% year on year

$VIRSCEND EDU (01565.HK)$The adjusted net profit for the year was 57.22 million yuan, up 373.3% year on year

IPO

$Xiamen Yan Palace Bioengineering Co Ltd (810491.HK)$Starting November 30, the IPO price is HK$8.8-11 per share

$FUJING HOLDINGS (02497.HK)$Starting November 30, the prospectus price is HK$1.08-1.28 per share

Company matters

$NCI (01336.HK)$To jointly fund the establishment of a private equity fund with China Life Insurance, both parties plan to invest 25 billion yuan each

$SISRAM MED (01696.HK)$: The registration application for Profhilo, an injectable filler product exclusively represented by the company in mainland China, was accepted by the State Drug Administration

$OCUMENSION-B (01477.HK)$: The enrollment of patients in OT-502 phase III clinical trials in China has been completed

Equity incentives

$SIPAI HEALTH (00314.HK)$The trustees purchased a total of 5,514,000 shares under the 2023 Stock Award Plan

Repurchase cancellation

$YANKUANG ENERGY (01171.HK)$Controlling shareholders plan to spend RMB 300 million to increase their holdings of the company's A shares and H shares

$TENCENT (00700.HK)$On November 29, 1.26 million shares were repurchased at a cost of HK$400 million

$AIA (01299.HK)$On November 29, 1,934,400 shares were repurchased at a cost of HK$135 million

$YUM CHINA (09987.HK)$On November 28, 316,000 shares were repurchased at a cost of 14 million US dollars

$HSBC HOLDINGS (00005.HK)$Repurchase of 1,162 million shares at a cost of HK$69.5333,900 on November 28

$SINOPEC CORP (00386.HK)$On November 29, it spent HK$38.909 million to repurchase 9.676 million shares

$ESR (01821.HK)$Repurchase of 3 million shares at a cost of HK$29.85 million on November 29

$KUAISHOU-W (01024.HK)$Repurchase of 500,000 shares at a cost of HK$28.31 million on November 29

$JIUMAOJIU (09922.HK)$On November 29, 2,632 million shares were repurchased at a cost of HK$206.32 million

$COSCO SHIP HOLD (01919.HK)$On November 29, 2.41 million shares were repurchased at a cost of HK$1,7039,700

$CHOW TAI FOOK (01929.HK)$On November 29, 1.44 million shares were repurchased at a cost of HK$15.945 million

$BEKE-W (02423.HK)$On November 28, 378,000 shares were repurchased at a cost of 2 million US dollars

$CONCORD NE (00182.HK)$Repurchase of 14.44 million shares at a cost of HK$9.55 million on November 29

Editor/Somer

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment